![](https://www.diabetesnews.com/wp-content/uploads/2014/02/Generic-pills-150x150.jpg)
The drugs in question, called GLP-1 medicines, help spur insulin production after meals. Nine are approved in Europe and seven in the U.S., including include Merck’s Januvia and Janumet, Novo Nordisk’s Victoza and Bristol-Myers Squibb’s Byetta and Bydureon.
Read more